Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1

被引：0
|
作者：
Catamero, Donna [1 ]
Purcell, Kiah [2 ]
Ray, Chloe [2 ]
Giacoia, Leora [2 ]
Leahey, Sheryl [3 ]
Born, Patricia [4 ]
Kruyswijk, Sandy [5 ]
机构：
[1] Mt Sinai Hlth Syst, New York, NY USA
[2] Mt Sinai Sch Med, New York, NY USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Hosp Wurzburg, Wurzburg, Germany
[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NSP-03
引用
收藏
页码：S314 / S315
页数：2
相关论文
共 50 条
  • [1] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
    Schinke, C.
    Touzeau, C.
    Minnema, M. C.
    van de Donk, N. W.
    Rodriguez-Otero, P.
    Mateos, M. -V.
    Rasche, L.
    Ye, J. C.
    Vishwamitra, D.
    Ma, X.
    Qin, X.
    Campagna, M.
    Masterson, T.
    Hilder, B.
    Tolbert, J.
    Renaud, T.
    Goldberg, J.
    Heuck, C.
    Chari, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
  • [2] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
    Schinke, Carolina D.
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Rasche, Leo
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Ma, Xuewen
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara J.
    Hilder, Brandi
    Tolbert, Jaszianne A.
    Renaud, Thomas
    Goldberg, Jenna
    Heuck, Christoph
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study
    Ito, Shigeki
    Kuroda, Yoshiaki
    Sunami, Kazutaka
    Matsue, Kosei
    Imada, Kazunori
    Tamura, Hideto
    Takamoto, Mikihiro
    Yamazaki, Hiroshi
    Fujikawa, Ei
    Pei, Lixia
    Masterson, Tara J.
    Campagna, Michela
    Lau, Bonnie W.
    Takamatsu, Yasushi
    BLOOD, 2024, 144 : 7011 - 7012
  • [4] Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
    Purcell, Kiah
    Catamero, Donna
    Dai, Victoria
    Feuer, Julia
    Giacoia, Leora
    Leon, Yan
    Lurie, Alaina
    Mitchell, Emily
    Ray, Chloe
    Urena, Annel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S313
  • [5] MANAGEMENT CONSIDERATIONS FOR DERMATOLOGIC TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA
    Esler, Elaine
    Ray, Chloe
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    McCluggage, Julie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [6] MANAGEMENT CONSIDERATIONS FOR ORAL TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Shenoy, Samantha
    Leahey, Sheryl
    Catamero, Donna
    O'Rourke, Lisa
    Gray, Kathleen
    Rogers, Stephanie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [7] Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
    Ye, Jing Christine
    Schinke, Carolina
    Touzeau, Cyrille
    Minnema, Monique
    van de Donk, Niels
    Rodriguez-Otero, Paula
    Mateos Manteca, Maria-Victoria
    Rasche, Leo
    Vishwamitra, Deeksha
    Singh, Indrajeet
    Qin, Xiang
    Campagna, Michela
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S99
  • [8] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Rasche, Leo
    Schinke, Carolina
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Singh, Indrajeet
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Hilder, Brandi W.
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
  • [9] Updated Results of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
    Jakubowiak, Andrzej J.
    Anguille, Sebastien
    Karlin, Lionel
    Chari, Ajai
    Schinke, Carolina
    Rasche, Leo
    San-Miguel, Jesus
    Campagna, Michela
    Hilder, Brandi W.
    Masterson, Tara J.
    Qin, Xiang
    Renaud, Thomas
    Tolbert, Jaszianne
    Vishwamitra, Deeksha
    Skerget, Sheri
    Moreau, Philippe
    BLOOD, 2023, 142
  • [10] Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
    Verkleij, Christie P. M.
    Broekmans, Marloes E. C.
    van Duin, Mark
    Frerichs, Kristine A.
    Kuiper, Rowan
    de Jonge, A. Vera
    Kaiser, Martin
    Morgan, Gareth
    Axel, Amy
    Boominathan, Rengasamy
    Sendecki, Jocelyn
    Wong, Amy
    Verona, Raluca, I
    Sonneveld, Pieter
    Zweegman, Sonja
    Adams, Homer C., III
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    BLOOD ADVANCES, 2021, 5 (08) : 2196 - 2215
12345